Brief: Nanobiotix Announces Completion Of Phase 1 Dose Escalation And Nbtxr3 Recommended Phase 2 Dose For A Type Of Lung Cancer
02/04/2024 21:21
April 2 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES COMPLETION OF PHASE 1 DOSE ESCALATION
AND
NBTXR3 RECOMMENDED PHASE 2 DOSE FOR THE TREATMENT OF INOPERABLE,
RECURRENT LUNG CANCER IN PATIENTS AMENABLE TO RE-IRRADIATION
Source text for Eikon: ID:nGNX1Y5V6M
Further company coverage: NANOB.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering